MX2011008344A - Composiciones de dosis orales de liberacion retardada que contiene bardoloxona-metilo (cddo-me) amorfo. - Google Patents
Composiciones de dosis orales de liberacion retardada que contiene bardoloxona-metilo (cddo-me) amorfo.Info
- Publication number
- MX2011008344A MX2011008344A MX2011008344A MX2011008344A MX2011008344A MX 2011008344 A MX2011008344 A MX 2011008344A MX 2011008344 A MX2011008344 A MX 2011008344A MX 2011008344 A MX2011008344 A MX 2011008344A MX 2011008344 A MX2011008344 A MX 2011008344A
- Authority
- MX
- Mexico
- Prior art keywords
- oral dosage
- delayed release
- dosage compositions
- contain amorphous
- cddo
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Las formulaciones farmacéuticas exhiben una Cmax deseablemente baja, entre otras propiedades, que contienen partículas de bardoxolona-metilo amorfo, ya sea en forma pura o en la forma de una dispersión sólida, mezcladas con partículas de un agente aglutinante hidrófilo. Estas formulaciones poseen la ventaja de mayor biodisponibilidad oral, con relación a las formulaciones basadas en la forma cristalina de bardoxolona-metilo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15260809P | 2009-02-13 | 2009-02-13 | |
| PCT/US2010/024127 WO2010093944A2 (en) | 2009-02-13 | 2010-02-12 | Delayed release, oral dosage compositions that contain amorphous cddo-me |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011008344A true MX2011008344A (es) | 2011-09-29 |
Family
ID=42335073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011008344A MX2011008344A (es) | 2009-02-13 | 2010-02-12 | Composiciones de dosis orales de liberacion retardada que contiene bardoloxona-metilo (cddo-me) amorfo. |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US8747901B2 (es) |
| EP (2) | EP2395979B1 (es) |
| JP (1) | JP5775464B2 (es) |
| KR (2) | KR101483203B1 (es) |
| CN (2) | CN102387789A (es) |
| AU (1) | AU2010213594B2 (es) |
| BR (1) | BRPI1008023B8 (es) |
| CA (1) | CA2752048C (es) |
| CO (1) | CO6361904A2 (es) |
| CY (2) | CY1119595T1 (es) |
| DK (2) | DK2395979T3 (es) |
| EA (1) | EA023652B1 (es) |
| ES (2) | ES2731601T3 (es) |
| HK (1) | HK1220130A1 (es) |
| HR (2) | HRP20171639T1 (es) |
| HU (2) | HUE035013T2 (es) |
| IL (1) | IL214258A (es) |
| LT (2) | LT2395979T (es) |
| MX (1) | MX2011008344A (es) |
| MY (1) | MY173715A (es) |
| NO (1) | NO2395979T3 (es) |
| NZ (1) | NZ594488A (es) |
| PL (2) | PL2395979T3 (es) |
| PT (2) | PT2395979T (es) |
| SG (1) | SG173601A1 (es) |
| SI (2) | SI2395979T1 (es) |
| SM (2) | SMT201900432T1 (es) |
| TR (1) | TR201909743T4 (es) |
| WO (1) | WO2010093944A2 (es) |
| ZA (1) | ZA201105630B (es) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6326507B1 (en) | 1998-06-19 | 2001-12-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
| KR101780382B1 (ko) | 2008-01-11 | 2017-10-10 | 리타 파마슈티컬스 잉크. | 합성 트리테르페노이드 및 질병 치료시의 사용 방법 |
| CN103588678A (zh) | 2008-04-18 | 2014-02-19 | 里亚塔医药公司 | 包含抗炎症药效团的化合物以及使用方法 |
| RS55631B1 (sr) | 2008-04-18 | 2017-06-30 | Reata Pharmaceuticals Inc | Antioksidansni modulatori upale: c-17 homologisani derivati oleanolinske kiseline |
| RS58392B1 (sr) | 2008-04-18 | 2019-04-30 | Reata Pharmaceuticals Inc | Antioksidantni modulatori inflamacije: derivati oleanoličke kiseline sa amino i drugim modifikacijama na c-17 |
| CN102164941B (zh) | 2008-04-18 | 2015-05-27 | 里亚塔医药公司 | 抗氧化剂炎症调节剂:具有饱和c环的齐墩果酸衍生物 |
| AU2009274037B2 (en) | 2008-07-22 | 2015-07-09 | Trustees Of Dartmouth College | Monocyclic cyanoenones and methods of use thereof |
| MX2011008344A (es) | 2009-02-13 | 2011-09-29 | Reata Pharmaceuticals Inc | Composiciones de dosis orales de liberacion retardada que contiene bardoloxona-metilo (cddo-me) amorfo. |
| AU2011240690C1 (en) | 2010-04-12 | 2014-11-06 | Reata Pharmaceuticals Holdings, LLC | Method of treating obesity using antioxidant inflammation modulators |
| CA2822071C (en) | 2010-12-17 | 2019-07-16 | Reata Pharmaceuticals, Inc. | Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators |
| PL2683731T3 (pl) | 2011-03-11 | 2019-09-30 | Reata Pharmaceuticals, Inc. | C4-monometylowe pochodne triterpenoidów i sposoby ich zastosowania |
| CN103156861B (zh) * | 2011-12-08 | 2015-11-25 | 陈丽梅 | 齐敦果酸衍生物及其可药用盐在治疗糖尿病眼病中的应用 |
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| US9504679B2 (en) | 2011-12-19 | 2016-11-29 | Bjoern Colin Kahrs | Pharmaceutical compositions comprising glitazones and Nrf2 activators |
| WO2013163344A1 (en) | 2012-04-27 | 2013-10-31 | Reata Pharmaceuticals, Inc. | 2.2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof |
| US8921419B2 (en) | 2012-05-08 | 2014-12-30 | Trustees Of Dartmouth College | Triterpenoids and compositions containing the same |
| US8981144B2 (en) | 2012-05-08 | 2015-03-17 | Trustees Of Dartmouth College | Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof |
| US9556222B2 (en) | 2012-06-15 | 2017-01-31 | Reata Pharmaceuticals, Inc. | A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof |
| AU2013312106B2 (en) | 2012-09-10 | 2018-03-08 | Reata Pharmaceuticals, Inc. | C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof |
| WO2014040073A1 (en) | 2012-09-10 | 2014-03-13 | Reata Pharmaceuticals, Inc. | C13-hydroxy derivatives of oleanolic acid and methods of use thereof |
| US9512094B2 (en) | 2012-09-10 | 2016-12-06 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
| TWI649330B (zh) | 2013-04-24 | 2019-02-01 | 艾伯維有限公司 | 甲基巴多索龍之２，２－二氟丙醯胺衍生物、其多晶形及其使用方法 |
| CN112870202A (zh) | 2013-08-23 | 2021-06-01 | 里亚塔医药公司 | 使用甲基巴多索隆或其类似物治疗和预防肾病的方法 |
| WO2016070063A1 (en) | 2014-10-31 | 2016-05-06 | The Regents Of The University Of California | Compositions and methods for treating hiv-associated cognitive dysfunction |
| JP6748652B2 (ja) | 2015-02-12 | 2020-09-02 | リアタ ファーマシューティカルズ インコーポレイテッド | 抗酸化性炎症調節剤としてのイミダゾリル三環式エノン |
| NZ741082A (en) | 2015-09-23 | 2023-06-30 | Reata Pharmaceuticals Inc | C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses |
| MX2019005401A (es) | 2016-11-08 | 2019-08-05 | Reata Pharmaceuticals Inc | Metodos para tratar el sindrome de alport con bardoxolona metilo o analogos de la misma. |
| TWI831738B (zh) | 2016-12-16 | 2024-02-11 | 美商瑞塔醫藥有限責任公司 | 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物 |
| EP3652193A1 (en) | 2017-07-13 | 2020-05-20 | Pliva Hrvatska D.O.O. | New crystalline polymorphs of bardoxolone methyl |
| ES2967689T3 (es) | 2018-04-06 | 2024-05-03 | Capsugel Belgium Nv | Proceso de secado por aspersión para partículas de baja relación de aspecto que comprenden poli[(metacrilato de metilo)-co-(ácido metacrílico)] |
| CA3103726A1 (en) | 2018-06-15 | 2019-12-19 | Reata Pharmaceuticals, Inc. | Pyrazole and imidazole compounds for inhibition of il-17 and rorgamma |
| EP3810141A1 (en) | 2018-06-20 | 2021-04-28 | Reata Pharmaceuticals, Inc. | Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith |
| CN113164436A (zh) | 2018-11-27 | 2021-07-23 | 协和麒麟株式会社 | 药物组合物 |
| CA3144603C (en) | 2019-07-19 | 2025-10-21 | Reata Pharmaceuticals, Inc. | C17 Polar Substitution Heteroaromatic Synthetic Triterpenoids and Their Methods of Use |
| AU2021273460A1 (en) | 2020-05-09 | 2022-12-08 | Reata Pharmaceuticals Holdings, LLC | Methods of treating covid-19 using bardoxolone methyl or analogs thereof |
| EP4259155A1 (en) | 2020-12-11 | 2023-10-18 | Reata Pharmaceuticals Holdings, LLC | Synthetic triterpenoids for use in therapy |
| CN114558019A (zh) * | 2022-03-26 | 2022-05-31 | 中国科学院昆明动物研究所 | 一种Rab13基因抑制剂及应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6326507B1 (en) | 1998-06-19 | 2001-12-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
| US7435755B2 (en) * | 2000-11-28 | 2008-10-14 | The Trustees Of Dartmouth College | CDDO-compounds and combination therapies thereof |
| JP2008110962A (ja) * | 2006-08-02 | 2008-05-15 | Santen Pharmaceut Co Ltd | Ｎｒｆ２活性化物質を有効成分として含む角結膜障害の予防または治療剤 |
| JP4315182B2 (ja) * | 2006-10-30 | 2009-08-19 | ミツミ電機株式会社 | カメラモジュール |
| WO2008111497A1 (ja) * | 2007-03-08 | 2008-09-18 | Santen Pharmaceutical Co., Ltd. | トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤 |
| US8088824B2 (en) | 2007-08-15 | 2012-01-03 | Reata Pharmaceuticals Inc. | Forms of CDDO methyl ester |
| KR101780382B1 (ko) * | 2008-01-11 | 2017-10-10 | 리타 파마슈티컬스 잉크. | 합성 트리테르페노이드 및 질병 치료시의 사용 방법 |
| MX2011008344A (es) | 2009-02-13 | 2011-09-29 | Reata Pharmaceuticals Inc | Composiciones de dosis orales de liberacion retardada que contiene bardoloxona-metilo (cddo-me) amorfo. |
-
2010
- 2010-02-12 MX MX2011008344A patent/MX2011008344A/es active IP Right Grant
- 2010-02-12 CA CA2752048A patent/CA2752048C/en active Active
- 2010-02-12 PT PT107042988T patent/PT2395979T/pt unknown
- 2010-02-12 EA EA201190092A patent/EA023652B1/ru not_active IP Right Cessation
- 2010-02-12 WO PCT/US2010/024127 patent/WO2010093944A2/en not_active Ceased
- 2010-02-12 KR KR1020117021250A patent/KR101483203B1/ko active Active
- 2010-02-12 PL PL10704298T patent/PL2395979T3/pl unknown
- 2010-02-12 EP EP10704298.8A patent/EP2395979B1/en active Active
- 2010-02-12 JP JP2011550279A patent/JP5775464B2/ja active Active
- 2010-02-12 SG SG2011057122A patent/SG173601A1/en unknown
- 2010-02-12 ES ES17181174T patent/ES2731601T3/es active Active
- 2010-02-12 MY MYPI2011003694A patent/MY173715A/en unknown
- 2010-02-12 ES ES10704298.8T patent/ES2646816T3/es active Active
- 2010-02-12 KR KR1020147001850A patent/KR20140016441A/ko not_active Withdrawn
- 2010-02-12 SM SM20190432T patent/SMT201900432T1/it unknown
- 2010-02-12 TR TR2019/09743T patent/TR201909743T4/tr unknown
- 2010-02-12 PL PL17181174T patent/PL3254675T3/pl unknown
- 2010-02-12 CN CN201080007105XA patent/CN102387789A/zh active Pending
- 2010-02-12 SI SI201031570T patent/SI2395979T1/sl unknown
- 2010-02-12 NO NO10704298A patent/NO2395979T3/no unknown
- 2010-02-12 DK DK10704298.8T patent/DK2395979T3/da active
- 2010-02-12 PT PT17181174T patent/PT3254675T/pt unknown
- 2010-02-12 DK DK17181174.8T patent/DK3254675T3/da active
- 2010-02-12 SI SI201031906T patent/SI3254675T1/sl unknown
- 2010-02-12 SM SM20170527T patent/SMT201700527T1/it unknown
- 2010-02-12 HU HUE10704298A patent/HUE035013T2/en unknown
- 2010-02-12 LT LTEP10704298.8T patent/LT2395979T/lt unknown
- 2010-02-12 HU HUE17181174A patent/HUE044005T2/hu unknown
- 2010-02-12 EP EP17181174.8A patent/EP3254675B1/en active Active
- 2010-02-12 NZ NZ594488A patent/NZ594488A/xx unknown
- 2010-02-12 BR BRPI1008023A patent/BRPI1008023B8/pt active IP Right Grant
- 2010-02-12 LT LTEP17181174.8T patent/LT3254675T/lt unknown
- 2010-02-12 US US13/201,398 patent/US8747901B2/en active Active
- 2010-02-12 HR HRP20171639TT patent/HRP20171639T1/hr unknown
- 2010-02-12 AU AU2010213594A patent/AU2010213594B2/en active Active
- 2010-02-12 CN CN201510540397.8A patent/CN105232471A/zh active Pending
-
2011
- 2011-07-24 IL IL214258A patent/IL214258A/en active IP Right Grant
- 2011-07-29 ZA ZA2011/05630A patent/ZA201105630B/en unknown
- 2011-08-09 CO CO11100847A patent/CO6361904A2/es not_active Application Discontinuation
-
2014
- 2014-04-30 US US14/266,031 patent/US9155721B2/en active Active
-
2016
- 2016-07-13 HK HK16108241.2A patent/HK1220130A1/zh unknown
-
2017
- 2017-11-13 CY CY20171101183T patent/CY1119595T1/el unknown
-
2019
- 2019-06-17 HR HRP20191092 patent/HRP20191092T1/hr unknown
- 2019-07-17 CY CY20191100761T patent/CY1122066T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY173715A (en) | Delayed release, oral dosage compositions that contain amorphous cddo-me | |
| WO2009063222A3 (en) | Solid compositions | |
| WO2011106478A3 (en) | Apixaban formulations | |
| MY156888A (en) | Solid Compositions | |
| WO2010149169A3 (en) | Controlled release formulations | |
| PH12012502442A1 (en) | Solid compositions | |
| AU2011336397A8 (en) | Chemokine CXCR4 receptor modulators and uses related thereto | |
| WO2012021715A3 (en) | Stable formulations of linaclotide | |
| WO2011104652A3 (en) | Veterinary compositions | |
| WO2012085927A3 (en) | Tadalafil compositions | |
| IL201465A0 (en) | Self-precipitating pharmaceutical formulations for the modified release of active principle | |
| WO2012074830A3 (en) | Modified release tranexamic acid formulation | |
| AU2010321366A8 (en) | Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use | |
| WO2012029074A3 (en) | Pharmaceutical compositions of linezolid | |
| WO2014009970A3 (en) | Linagliptin solid dispersion | |
| WO2011066390A3 (en) | Nanoscale adjuvants and related pharmaceutical compositions and methods | |
| MX2012002706A (es) | Base de goma. | |
| WO2013095042A3 (ko) | 이매티닙메실산염 함유 과립, 이를 포함하는 경구용 속방성 정제 조성물 및 그것의 제조방법 | |
| WO2011107922A3 (en) | Extended release composition of milnacipran | |
| HK1140942A (en) | Self-precipitating pharmaceutical formulations for the modified release of active principle | |
| HK1171733A (en) | Methods, compounds, and compositions for delivering 1,3-propan ed isulfonic acid | |
| WO2013013657A8 (de) | Verpresste feste pharmazeutische zusammensetzung, umfassend amorphes partikuläres valsartan als wirkstoff |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |